BioCentury
ARTICLE | Clinical News

Panacos up on Phase IIa HIV data

August 23, 2005 12:22 AM UTC

PANC rose $3.25 (46%) to $10.30 on 27.8 million shares on Monday after its PA-457 met the primary endpoint in a Phase IIa trial. In the double-blind, U.S. trial in 33 patients, the median reduction in viral load was 90% for patients receiving the high dose (200 mg) of PA-457. The compound binds an immature form of the HIV capsid protein and blocks the production of infectious particles. ...